cilostazol has been researched along with 6-ketoprostaglandin f1 alpha in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikegami, T; Mizutani, M; Okuda, Y; Ueno, E; Yamashita, K | 1 |
| Chijiwa, T; Igawa, T; Kato, S; Kawamura, K; Kimura, Y; Shimidzu, S; Shiragiku, T; Tani, T; Unemi, F | 1 |
2 other study(ies) available for cilostazol and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Arteries; Blood Glucose; Cilostazol; Diabetic Neuropathies; Female; Hemodynamics; Humans; Male; Middle Aged; Tetrazoles; Thromboxane B2; Vasodilator Agents | 1992 |
Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 6-Ketoprostaglandin F1 alpha; Adenosine Diphosphate; Alprostadil; Azoles; Cells, Cultured; Cilostazol; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Thromboxane B2 | 1990 |